



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/197373/>

Version: Accepted Version

Article:

Kaura, V and Hopkins, PM (2020) Sevoflurane may not be a complete sigh of relief in COVID-19. *British Journal of Anaesthesia*, 125 (6). e487-e488. ISSN: 0007-0912

<https://doi.org/10.1016/j.bja.2020.09.012>

©2023, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>. This is an author produced version of an article published in the *British Journal of Anaesthesia*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Sevoflurane may not be a complete sigh of relief in COVID-19.

Vikas Kaura*¹, Philip M Hopkins¹

¹Academic unit of Anaesthesia,
Leeds Institute of Medical Research at St James's,
University of Leeds,
Leeds,
UK.

* vkaura@doctors.org.uk

@vikaskaura1

Keywords

COVID-19, ICU, Malignant Hyperthermia, Sedation, Sevoflurane, Volatile anaesthetics.

Dear Editor,

We read with interest the editorial by Nieuwenhuijs-Moeke¹ and colleagues on the use of sevoflurane as an Intensive care unit (ICU) sedative in patients admitted with COVID-19. However, we were surprised that there was no mention of the potential for a fatal episode of malignant hyperthermia (MH) occurring when using a volatile anaesthetic agent as a sedative in the ICU.

Although rare, cases of MH triggered in the ICU do occur.² Unpublished data from the UK MH unit in Leeds shows that there have been two patients referred in the past five years following an MH episode as a result of exposure to a volatile anaesthetic agent in the ICU: in both cases the volatile anaesthetic was used to alleviate status asthmaticus. In one case the volatile anaesthetic was isoflurane and in the other, sevoflurane. As previously reported³, sevoflurane is now the most common triggering agent in new cases referred to the UK MH unit, supplanting isoflurane which however remains the most common triggering agent over the last thirty years.

While we do not suggest that the possibility of an MH reaction should be the over-riding factor in the choice of ICU sedative, use of volatile anaesthetics in this setting should be accompanied by education of ICU staff in the recognition and management of an MH reaction⁴. Display of visual aids for diagnosis and management in the relevant bed-space might also be considered (these can be downloaded from www.ukmhr.ac.uk). Furthermore, it should be noted that an MH reaction within the ICU may be more difficult to diagnose than in the operating theatre because of a high incidence of conditions that are associated with clinical features of MH (hypercarbia, tachycardia, raised temperature, hypoxaemia, acidosis, hyperkalaemia⁴) such as sepsis, respiratory failure, or acute kidney injury: each of these is frequently observed in critically ill COVID-19 patients.⁵ Also available should be adequate stocks of dantrolene⁶ and activated charcoal filters.⁷

One fascinating piece of information that has emerged from population genome and exome sequencing projects is the high population incidence (1:1500) of genetic variants associated with susceptibility to MH.⁸ It is likely that there are genetic and non-genetic factors

contributing to the discrepancy between the prevalence of such genetic variants and the incidence of clinical MH⁹, but these are unknown. It is possible that the non-genetic contributors to triggering may be more common in critically ill patients, so while the current low incidence of MH in the ICU setting is likely to reflect the infrequency of use of volatile anaesthetic sedation in the ICU, an increase in this practice may reveal that critically ill MH susceptible patients have a greater chance of triggering than in the operating theatre.

Consequently, intensivists and ICU nurses should be added to anaesthetists, pre-hospital practitioners and emergency room physicians in the list of practitioners who need to be explicitly aware that MH reactions are still occurring, and these can be triggered by the use of any of the volatile anaesthetic agents which includes methoxyflurane¹⁰, and the depolarising muscle relaxant succinylcholine.⁴

References:

1. Nieuwenhuijs-Moeke GJ, Jainandunsing JS, Struys MMRF. Sevoflurane, a sigh of relief in COVID-19? *Br J Anaesth* 2020; **125**: 118-121.
2. Schuster F, Moegele S, Johannsen S, Roewer N. Malignant hyperthermia in the intensive care setting. *Crit Care* 2014; **18**: 411.
3. Kaura V, Aboelsaod EM, Hopkins PM. Has malignant hyperthermia really disappeared with halothane? *Br J Anaesth* 2018; **121**: 980-81
4. Gupta PK, Hopkins PM. Diagnosis and management of malignant hyperthermia. *BJA Education* 2017; **17**: 249-54
5. Phua J, Weng L, Ling L, Moritoki E, Lim C, Vasishtha J, *et al.* Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. *Lancet Respir Med* 2020; **8**: 506-17.
6. Glahn KPE, Bendixen D, Girard T, Hopkins PM, Johannsen S, Ruffert H, *et al.* Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. *Br J Anaesth* 2020; **125**: 133-40.
7. Bilmen JG, Hopkins PM. The use of charcoal filters in malignant hyperthermia: Have they found their place? *Anaesthesia* 2019; **74**: 13-16.

8. Biesecker LG, Dirksen RT, Girard T, Hopkins PM, Riazi S, Rosenberg H, *et al.* Genomic Screening for Malignant Hyperthermia Susceptibility. *Anesthesiology* 2020. Advance online publication. <https://doi.org/10.1097/ALN.0000000000003547>.
9. Shaw MA, Hopkins PM. Mission impossible or mission futile? Estimating penetrance for malignant hyperthermia. *Anesthesiology* 2019; **131**: 957-9.
10. Jephcott C, Grummet J, Nguyen N, Spruyt O. A review of the safety and efficacy of inhaled methoxyflurane as an analgesic for outpatient procedures. *Br J Anaesth* 2018; **120**: 1040-48.